Abstract
Neuroblastoma, which arises from sympathetic neural precursors, is the most common childhood cancer. The prognosis of advanced neuroblastoma remains poor even with intensive therapy. To develop new therapeutic agents, researchers have explored the molecular pathogenesis of neuroblastoma. Animal models of neuroblastoma are an indispensable tool for neuroblastoma research. This chapter reviews neuroblastoma mouse models, ranging from classic xenograft models to recently-developed genetically-engineered mouse models, discusses the insight obtained from these mouse models.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aguzzi A, Wagner EF, Williams RL, Courtneidge SA (1990) Sympathetic hyperplasia and neuroblastomas in transgenic mice expressing polyoma middle T antigen. New Biol 2(6):533–543
Alam G, Cui H, Shi H, Yang L, Ding J, Mao L, Maltese WA, Ding HF (2009) MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am J Pathol 175(2):856–866
Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3(3):203–216
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653):1121–1124
Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, Weiss WA, Khachigian LM, Norris MD, Haber M (2003) Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95(18):1394–1403
Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM (2009) Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia 11(8):753–762
Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA (2007) Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67(19):9435–9442
Dyer MA (2004) Mouse models of childhood cancer of the nervous system. J Clin Pathol 57(6):561–576
Feigenbaum L, Hinrichs SH, Jay G (1992) JC virus and simian virus 40 enhancers and transforming proteins: role in determining tissue specificity and pathogenicity in transgenic mice. J Virol 66(2):1176–1182
Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17(6):1815–1824
Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA (2003) Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 63(17):5266–5273
Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, Haber M, Armati PJ, Weiss WA, Marshall GM (2004) Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci USA 101(34):12664–12669
Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, London WB, Buxton A, Gilmour SK, Marshall GM, Haber M (2008) ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68(23):9735–9745
Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA (2007) The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49(7):928–940
Ikeda I, Ishizaka Y, Tahira T, Suzuki T, Onda M, Sugimura T, Nagao M (1990) Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. Oncogene 5(9):1291–1296
Iwakura H, Ariyasu H, Kanamoto N, Hosoda K, Nakao K, Kangawa K, Akamizu T (2008) Establishment of a novel neuroblastoma mouse model. Int J Oncol 33(6):1195–1199
Iwamoto T, Taniguchi M, Wajjwalku W, Nakashima I, Takahashi M (1993) Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene. Br J Cancer 67(3):504–507
Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84(10):1424–1431
Kohl NE, Gee CE, Alt FW (1984) Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 226(4680):1335–1337
Koike K, Jay G, Hartley JW, Schrenzel MD, Higgins RJ, Hinrichs SH (1990) Activation of retrovirus in transgenic mice: association with development of olfactory neuroblastoma. J Virol 64(8):3988–3991
Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369(9579):2106–2120
Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ (2010) Initial testing of the Aurora Kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55(1):26–34
Pecori Giraldi F, Mizobuchi M, Horowitz ZD, Downs TR, Aleppo G, Kier A, Wagner T, Yun JS, Kopchick JJ, Frohman LA (1994) Development of neuroepithelial tumors of the adrenal medulla in transgenic mice expressing a mouse hypothalamic growth hormone-releasing hormone promoter-simian virus-40 T-antigen fusion gene. Endocrinology 134(3):1219–1224
Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA (1994) A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91(20):9626–9630
Servenius B, Vernachio J, Price J, Andersson LC, Peterson PA (1994) Metastasizing neuroblastomas in mice transgenic for simian virus 40 large T (SV40T) under the olfactory marker protein gene promoter. Cancer Res 54(19):5198–5205
Skalnik DG, Dorfman DM, Williams DA, Orkin SH (1991) Restriction of neuroblastoma to the prostate gland in transgenic mice. Mol Cell Biol 11(9):4518–4527
Small JA, Khoury G, Jay G, Howley PM, Scangos GA (1986) Early regions of JC virus and BK virus induce distinct and tissue-specific tumors in transgenic mice. Proc Natl Acad Sci USA 83(21):8288–8292
Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, de Pontual L, Schleiermacher G, Coze C, Philip N, Frebourg T, Munnich A, Lyonnet S, Delattre O, Amiel J (2004) Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 74(4):761–764
Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, Combaret V, Delattre O, Feuerstein BG, Plantaz D (2001) Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med Pediatr Oncol 36(1):5–10
Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985–2995
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Iwakura, H., Akamizu, T. (2012). Neuroblastoma Mouse Model. In: Hayat, M. (eds) Neuroblastoma. Pediatric Cancer, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2418-1_4
Download citation
DOI: https://doi.org/10.1007/978-94-007-2418-1_4
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2417-4
Online ISBN: 978-94-007-2418-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)